Market Overview - U.S. equity markets in Q4 2025 were influenced by optimism regarding potential monetary easing and caution related to economic growth and valuations [1] - Early gains were attributed to strong AI-related earnings and a rate cut by the U.S. Federal Reserve in October, but sentiment cooled later due to mixed signals from the Fed [1] - Large-cap stocks rose 17.4% for the year and 2.4% in the quarter, while small caps gained 12.8% for the year and 2.2% in the quarter [1] - Value stocks outperformed growth stocks, returning 3.3% versus 1.2% for the quarter [1] Fund Performance - Meridian Growth Fund delivered a return of -0.39% (net) in the quarter, underperforming the Russell 2500 Growth Index's return of 0.33% [1] - The firm is monitoring factors affecting market returns, including potential changes in monetary policy and the sustainability of AI investments due to high valuations among hyperscalers [1] Company Spotlight: Exact Sciences Corporation - Exact Sciences Corporation (NASDAQ:EXAS) is recognized as a leading contributor to the Meridian Growth Fund, specializing in cancer screening and diagnostic test products [2][3] - As of January 26, 2026, Exact Sciences' stock closed at $102.51 per share, with a one-month return of 0.60% and an impressive 85.00% increase in value over the last 52 weeks [2] - The company has a market capitalization of $19.468 billion [2] - Exact Sciences is best known for its at-home colorectal cancer screening test, Cologuard, and saw stock performance improve due to signs of growth and the introduction of a new test [3] - The stock performance was further enhanced by Abbott's announcement to acquire Exact Sciences at a significant premium [3]

Group 1 - The article does not contain relevant content regarding company or industry insights [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - The Alger Small Cap Focus Fund's fourth-quarter 2025 investor letter indicates a strong performance in the US equity market, with the S&P 500 rising by 2.7% due to better-than-expected corporate earnings and a supportive macroeconomic environment [1] - The letter highlights a divergence in market performance, particularly regarding AI investments, which face skepticism due to various challenges [1] - The Fund's Class A shares outperformed the Russell 2000 Growth Index, with contributions from the Utilities and Financials sectors, while Consumer Discretionary and Information Technology sectors negatively impacted performance [1] Company Insights - Exact Sciences Corporation (NASDAQ:EXAS) is noted for its cancer screening and diagnostic products, with a market capitalization of $19.453 billion [2] - The stock of Exact Sciences Corporation closed at $102.43 per share on January 16, 2026, with a one-month return of 0.60% and a remarkable 97.97% increase over the past 52 weeks [2] - The company is recognized for its Cologuard noninvasive colorectal cancer screening and has a pipeline that includes molecular residual disease (MRD) and multi-cancer early detection (MCED) testing [3] - Exact Sciences' stock saw positive contributions during the quarter following Abbott's announcement of a definitive all-cash acquisition agreement valued at approximately $21 billion, which provided a significant premium and drove the stock price higher [3]

Core Viewpoint - The proposed sale of Exact Sciences Corporation to Abbott Laboratories is under investigation to assess whether the offered price of $105.00 per share adequately reflects the company's value [1]. Group 1: Transaction Details - Exact Sciences shareholders will receive $105.00 in cash for each share they own as part of the proposed transaction [1]. - The law firm Kahn Swick & Foti, LLC is investigating the adequacy of this consideration and the process leading to the proposed sale [1]. Group 2: Legal Rights and Contact Information - Shareholders who believe the transaction undervalues the company can contact Kahn Swick & Foti to discuss their legal rights without any obligation or cost [2]. - Contact details for KSF Managing Partner Lewis S. Kahn are provided for shareholders to reach out regarding the investigation [2].

Group 1 - Narweena is an asset manager that focuses on identifying market dislocations due to poor understanding of long-term business prospects [1] - The firm aims to achieve excess risk-adjusted returns by targeting businesses with secular growth opportunities in markets with barriers to entry [1] - Narweena's investment strategy emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and long-term investment horizon [1] Group 2 - The firm prefers smaller cap stocks and markets where competitive advantages are not immediately apparent [1] - Narweena believes that an aging population, low population growth, and stagnating productivity will create new investment opportunities distinct from historical trends [1] - Many industries may experience stagnation or secular decline, which could paradoxically enhance business performance due to reduced competition [1] Group 3 - Some businesses may face rising costs and diseconomies of scale, while economies are increasingly dominated by asset-light businesses [1] - The declining need for infrastructure investments is leading to a situation where a large pool of capital is pursuing a limited set of investment opportunities, driving up asset prices and compressing risk premia [1] - Richard Durant, the leader of Narweena, holds degrees in engineering and finance and an MBA, and has passed the CFA exams [1]

Group 1: Market Overview - As of January 2, 2026, two stocks in the health care sector are signaling potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is a key momentum indicator that helps traders assess stock performance by comparing price strength on up days versus down days [2] Group 2: Company Analysis - Teva Pharmaceutical Industries Ltd - Teva Pharmaceutical's long-term issuer credit rating was upgraded by S&P Global Ratings from 'BB' to 'BB+' with a stable outlook [6] - Teva's stock has increased approximately 16% over the past month, reaching a 52-week high of $31.99 [6] - The current RSI value for Teva is 71.6, indicating it may be overbought [6] - Teva's shares closed at $31.21, reflecting a slight decline of 0.4% [6] - Teva has a momentum score of 92.72 and a value score of 27.43 [6] Group 3: Company Analysis - Exact Sciences Corp - Exact Sciences was involved in a significant acquisition by Abbott Laboratories, which agreed to purchase the company for $105 per common share, totaling an equity value of approximately $21 billion [6] - Exact Sciences' stock has gained around 7% over the past month, with a 52-week high of $102.00 [6] - The RSI value for Exact Sciences is 77.8, suggesting it is also potentially overbought [6] - Exact Sciences' shares closed at $101.56, down 0.3% [6]

Group 1 - As of January 2, 2026, two stocks in the health care sector are identified as potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is a key momentum indicator, with values above 70 indicating that a stock may be overbought [2] - Teva Pharmaceutical Industries Ltd has an RSI value of 71.6, with a recent stock price of $31.21, reflecting a 16% gain over the past month [6] - Exact Sciences Corp has an RSI value of 77.8, with a recent stock price of $101.56, reflecting a 7% gain over the past month [6] Group 2 - Teva's long-term issuer credit rating was upgraded to 'BB+' from 'BB' by S&P Global Ratings, with a stable outlook [6] - Abbott Laboratories agreed to acquire Exact Sciences for $105 per common share, totaling approximately $21 billion in equity value [6] - Exact Sciences has an estimated enterprise value of $23 billion following the acquisition announcement [6]

Core Viewpoint - Julie & Holleman LLP is investigating Abbott's proposed $21 billion acquisition of Exact Sciences Corp, raising concerns about the fairness of the $105 per share deal price, which may be undervalued compared to potential estimates of $136.25 per share [1][2][3] Group 1: Acquisition Details - The acquisition deal was announced in November 2025 and is expected to close in the second quarter of 2026 [2] - Exact Sciences filed a preliminary proxy statement with the SEC on December 29, 2025, indicating that no other bidders were considered during the acquisition process [2] Group 2: Legal Investigation - Julie & Holleman LLP is investigating potential claims regarding the apparent unfairness of the deal and possible conflicts of interest [3] - The firm has a history of securing hundreds of millions of dollars for clients in similar cases, indicating their experience in shareholder litigation [3][4]

Core Insights - Exact Sciences Corporation (EXAS) is positioned for growth due to ongoing investments in R&D and enhanced commercial capabilities, which are driving stronger adoption of Cologuard and narrowing the screening gap [1][10] - The stock has experienced a significant decline of 81.3% over the past year, contrasting with a 19.1% growth in the industry and a 19.5% rise in the S&P 500 [2] - EXAS has a market capitalization of $19.34 billion and an estimated long-term earnings growth rate of 30.3%, outperforming the industry's 22.1% growth [2] Growth Drivers - Enhancing Customer Experience: The company aims to transform cancer care by providing valuable insights to patients throughout their diagnosis and treatment, focusing on empowering patients and simplifying the testing process for physicians [4] - Advancing New Solutions: EXAS continues to invest in its pipeline, launching innovative tests such as Cancerguard, Oncodetect MRD, and Cologuard Plus, which are designed to improve cancer detection and screening practices [6][7][10] Challenges - Escalating Costs: The company faces pressures from global macroeconomic conditions, with costs of revenues rising by 22.8% and sales and marketing expenses increasing by 13.6% year over year [8][9] - Tough Competitive Landscape: EXAS operates in a highly competitive colorectal cancer screening market, facing challenges from competitors with greater financial resources, which could impact growth and profitability [11] Financial Estimates - The Zacks Consensus Estimate for EXAS' 2025 earnings remains unchanged at 27 cents, with projected revenues of $3.23 billion, indicating a 17.1% increase from 2024 [12]